Trial Profile
Comparison in the efficacy of the two add on therapies with an anticholinergic agent versus a beta3-adrenoceptor agonist for patients with benign prostatic enlargement complicated by overactive bladder after alpha1-blocker administration, A randomized, prospective trial using a urodynamic study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2020
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary) ; Mirabegron (Primary)
- Indications Overactive bladder
- Focus Pharmacodynamics
- 24 Dec 2020 Status changed from not yet recruiting to completed.
- 15 Mar 2017 New trial record